Mikrobiomik Healthcare Company S.L.
Quick facts
Phase 3 pipeline
- MBK-01 · Immunology / Gastroenterology
MBK-01 is a microbiome-based therapeutic that modulates the composition and function of the gut microbiota to restore immune homeostasis and reduce inflammation.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Mikrobiomik Healthcare Company S.L. portfolio CI brief
- Mikrobiomik Healthcare Company S.L. pipeline updates RSS
Frequently asked questions about Mikrobiomik Healthcare Company S.L.
What is Mikrobiomik Healthcare Company S.L.'s pipeline?
Mikrobiomik Healthcare Company S.L. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include MBK-01.
Related
- Sector hub: All tracked pharma companies